The Russian pharmaceutical market is positioned at the forefront of the pharma emerging markets, with the Government’s ambitious Pharma 2020 plan continuing apace. The demand for international pharmaceutical ingredients, manufacturing and packaging equipment is increasing in order to upgrade existing manufacturing sites to GMP standards. Russia’s 2020 plan, introduced in 2009, provides direct investment by the Government, with nearly US$ 5 billion in funding, and the goal of increasing domestic finished-dose pharmaceutical manufacturing and R&D capabilities.

The country has attracted a strong base of international pharma companies – an overwhelming 76 per cent of total pharmaceutical sales are attributed to imported drugs – with many more foreign manufacturers now looking to capitalise on this attractive market. Integral to the internationalization of this market is CPhI Russia, which acts a central hub for buyers and sellers within the region, providing a vital platform where pharma executives can connect, build and nurture existing relationships.

CPhI Russia @ IPhEB, organised by UBM EMEA, returns for the fourth consecutive year in Russia as business opportunities in the country remain diverse, with companies looking to gain access to the Commonwealth of Independent States (CIS) and Central East European (CEE) regions.

The event which is taking place at JSC VDNH (VVC), Moscow from March 30 to April 1, 2016 includes IPhEB Conference (forum), which provides key insights into the local market. One of the key sessions in this forum is a master class on strategy and procedure for companies and products ahead of market launch in the region. Market Access tactics and implementation will be developed at the master class, including how to evaluate the medical importance of a disease, therapeutic and pharma economic viability, its prevalence over the existing treatment methods, and availability.

Growth in the domestic market has enabled CPhI Russia @ IPhEB to expand year-on-year, and in 2016, the three-in-one event will welcome more than 3000 attendees – in 2015, 231 exhibitors attended from 67 different countries. Exhibitors include some of the largest companies in pharmaceutical ingredients, machinery, equipment and technology (P-MEC), packaging and drug delivery systems (InnoPack), alongside domestic heavyweights Pharmasyntez, Indukern, Protek-SVM, Merck, Serdix, Kelun Kazfarm, and Sotex.

Says Robert Rosen, Director General of Selecta (RUS) Company, Bind (RUS) "Last year was a very interesting event that facilitates the future development of science and pharmaceuticals. It helped our company to understand and find potential niches, research and administrative resources, and also business partners. CPhI Russia @ IPhEB provides all the opportunities for future, successful work. We are delighted to be returning to Moscow and actively contributing to new industry developments and Russia’s pharma expansion".